Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS 8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 9	NOV 26	MARPAT enhanced with FSORT command
NEWS 10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS 11	NOV 26	CHEMSAFE now available on STN Easy
NEWS 12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 13	DEC 01	ChemPort single article sales feature unavailable
NEWS 14	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 15	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 16	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 17	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:52:13 ON 13 JAN 2009

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 11:52:28 ON 13 JAN 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JAN 2009 HIGHEST RN 1093343-19-1
DICTIONARY FILE UPDATES: 12 JAN 2009 HIGHEST RN 1093343-19-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10587792.str



```
chain nodes :
7  8  12  19  22  23  24  41  56
ring nodes :
1  2  3  4  5  6  13  14  15  16  17  18  25  26  27  28  29  30  31  32  33  34
35  36  37  38  39  40  42  43  44  45  46  47  48  49  50  51
chain bonds :
1-8  4-7  5-22  12-13  17-19  22-23  23-24  24-56  36-41
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  13-14  13-18  14-15  15-16  16-17  17-18  25-26  25-
30
26-27  27-28  28-29  29-30  29-31  30-34  31-32  32-33  33-34  35-36  35-40  36-37
37-38  38-39
39-40  42-43  42-47  43-44  44-45  45-46  46-47  46-48  47-51  48-49  49-50  50-51
exact/norm bonds :
1-2  1-6  1-8  2-3  3-4  4-5  4-7  5-6  5-22  12-13  17-19  22-23  23-24  24-56
36-41  42-43  42-47  43-44  44-45  45-46
normalized bonds :
13-14  13-18  14-15  15-16  16-17  17-18  25-26  25-30  26-27  27-28  28-29  29-30
29-31  30-34  31-32  32-33  33-34  35-36  35-40  36-37  37-38  38-39  39-40  46-47
46-48  47-51
48-49  49-50  50-51
isolated ring systems :
containing 13 : 25 : 35 : 42 :


G1:S,N

G2:Ak,[*1]

G3:[*2],[*3],[*4]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  12:CLASS  13:Atom
14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:CLASS  22:CLASS  23:CLASS  24:CLASS
25:Atom  26:Atom
27:Atom  28:Atom  29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom
36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:CLASS  42:Atom  43:Atom  44:Atom  45:Atom  46:Atom
47:Atom
48:Atom  49:Atom  50:Atom  51:Atom  56:CLASS




L1      STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.48       0.70
```

FILE 'CAPLUS' ENTERED AT 11:52:55 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3
FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 11:53:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 706788 TO ITERATE

98.6% PROCESSED 696979 ITERATIONS 636 ANSWERS

100.0% PROCESSED 706788 ITERATIONS 636 ANSWERS
SEARCH TIME: 00.00.20

L2 636 SEA SSS FUL L1

L3 6 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:157019 CAPLUS Full-text
DOCUMENT NUMBER: 148:239201
TITLE: Preparation of imidazole or thiazole derivatives for treatment of pain or migraine
INVENTOR(S): Stoehr, Thomas; Rodriguez, Maria Luz Lopez; Salama, Bellinda Benhamu

PATENT ASSIGNEE(S): Schwarz Pharma S.L., Spain
SOURCE: PCT Int. Appl., 75pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008015538	A2	20080207	WO 2007-IB2194	20070731
WO 2008015538	A3	20080515		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-834384P P 20060731
US 2006-834385P P 20060731
OTHER SOURCE(S): MARPAT 148:239201
GI



I



II

AB The title compds. with general formula I [wherein R1 = H, -(CH2)3-, -(CH2)4-, -CH2SCH2-, or -SCH2CH2-; R2 = N or S; R3 = H, C1-C10 alkyl, aryl, or arylalkyl; R4 = O or CH2; R5 = (un)substituted Ph, naphthyl, pyridinyl, furanyl, etc.; Z = C2-C10 alkylene, C2-C10 alkenylene, or C2-C10 alkynylene; n = 0-1; m = 0-2] or pharmaceutically acceptable isomers, hydrates, solvates, or salts thereof were prepared for preventing or treating pain or migraine in a subject. General synthesis of I was discussed in the present invention with IR and NMR data reported. Compound II showed analgesic activities in formalin pain assay on male mouse with > 75% pain reduction in late phase, when administered by i.p. injection at 10 mg/kg.

IT 658714-55-7P 658714-57-9P 658714-58-0P
658714-60-4P 658714-66-0P 658714-67-1P
658714-76-2P 658714-78-4P 658714-79-5P
658714-80-8P 658714-81-9P 658714-88-6P
793666-55-4P 862589-93-3P 862589-94-4P
862589-96-6P 862589-98-8P 862590-00-9P
862590-02-1P 862590-04-3P 862590-06-5P
862590-07-6P 862590-10-1P 862590-11-2P
862590-13-4P 862590-15-6P 862590-17-8P
862590-18-9P 862590-20-3P 862590-21-4P
862590-23-6P 862590-25-8P 862590-28-1P
862590-30-5P 862590-32-7P 862590-33-8P
862590-34-9P 862590-35-0P 862590-37-2P
862590-38-3P 862590-39-4P 862590-40-7P
862590-41-8P 862590-42-9P 862590-43-0P
862590-44-1P 862590-45-2P 862590-46-3P
862590-47-4P 862590-48-5P 862590-49-6P
862590-50-9P 862590-51-0P 862590-52-1P
862590-53-2P 862590-54-3P 862590-57-6P
862590-58-7P 862590-59-8P 862590-60-1P
862590-61-2P 862590-62-3P 862590-63-4P
862590-64-5P 862590-65-6P 862590-66-7P
862590-67-8P 862590-68-9P 862590-69-0P
862590-70-3P 862590-71-4P 862590-72-5P
862590-73-6P 862590-74-7P 862590-75-8P
862590-76-9P 862590-77-0P 862590-78-1P
862591-00-2P 862645-79-2P 1005741-13-8P
1005741-16-1P 1005741-19-4P 1005741-24-1P
1005741-25-2P 1005741-26-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of imidazole or thiazole derivs. for treatment of pain or migraine)

RN 658714-55-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 658714-57-9 CAPLUS
CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)



RN 658714-58-0 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)



RN 658714-60-4 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]- (CA INDEX NAME)



RN 658714-66-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-67-1 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-76-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-78-4 CAPLUS
CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-79-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-80-8 CAPLUS
CN 2,4-Thiazolidinedione, 3-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-81-9 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-88-6 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 793666-55-4 CAPLUS
CN 2,4-Thiazolidinedione, 3-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]- (CA INDEX NAME)



RN 862589-93-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 862589-94-4 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 862589-96-6 CAPLUS
CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-98-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-00-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-02-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-04-3 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-06-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 862590-07-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro- (CA INDEX NAME)



RN 862590-10-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2E)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-11-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-13-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-15-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-17-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-18-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 862590-20-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 862590-21-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-23-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)



RN 862590-25-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-28-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



RN 862590-30-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



RN 862590-32-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-([1,1'-biphenyl]-2-yloxy)ethyl]amino]butyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-33-8 CAPLUS
CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-34-9 CAPLUS
CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-35-0 CAPLUS
CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-37-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-38-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-39-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2Z)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-40-7 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-41-8 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-42-9 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]-,

hydrochloride (1:1) (CA INDEX NAME)



RN 862590-43-0 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-44-1 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-45-2 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]-, hydrochloride (1:2)
(CA INDEX NAME)



●2 HCl

RN 862590-46-3 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 862590-47-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 862590-48-5 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-49-6 CAPLUS
CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro- (CA INDEX NAME)



RN 862590-50-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro- (CA INDEX NAME)



RN 862590-51-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro- (CA INDEX NAME)



RN 862590-52-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro- (CA INDEX NAME)



RN 862590-53-2 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]- (CA INDEX NAME)



RN 862590-54-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 862590-57-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2E)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-58-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,

tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-59-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-60-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-61-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-62-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-63-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-64-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-65-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-66-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-([1,1'-biphenyl]-2-yloxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-67-8 CAPLUS
CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



RN 862590-68-9 CAPLUS
CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



RN 862590-69-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-70-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-71-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2Z)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-72-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-73-6 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]- (CA INDEX NAME)



RN 862590-74-7 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]- (CA INDEX NAME)



RN 862590-75-8 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-76-9 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro- (CA INDEX NAME)



RN 862590-77-0 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)



RN 862590-78-1 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]- (CA INDEX NAME)



RN 862591-00-2 CAPLUS
CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester (CA INDEX NAME)



RN 862645-79-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 1005741-13-8 CAPLUS
CN Imidazo[5,1-b]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro- (CA INDEX NAME)



RN 1005741-16-1 CAPLUS
CN Imidazo[5,1-b]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 1005741-19-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1005741-24-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 1005741-25-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1005741-26-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:400379 CAPLUS Full-text
DOCUMENT NUMBER: 148:262581
TITLE: A novel process to prepare rosiglitazone maleate
INVENTOR(S): Bipin, Pandey; Bhushan, Lohray Braj; Bhushan, Lohray Vidya

PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
SOURCE: Indian Pat. Appl., 35pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2004MU00004	A	20060929	IN 2004-MU4	20040102
IN 2007MU00411	A	20081114	IN 2007-MU411	20070305
PRIORITY APPLN. INFO.:			IN 2004-MU4 A3	20040102

OTHER SOURCE(S): CASREACT 148:262581

AB The invention relates to process for the preparation of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino)ethoxy]benzyl]thiazolidine-2,4- dione, maleate namely Rosiglitazone maleate through intermediates. Rosiglitazone was prepared by reductive alkylation of 2-aminopyridine with formaldehyde and 5,5-dimethylhydantoin; the resulting 5,5-dimethyl-3-(pyridin-2-ylaminomethyl)imidazolidine-2,4-dione underwent reductive alkylation of 4-(2-bromoethoxy)benzaldehyde to give 4-[2-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)ethoxy]benzaldehyde,w which underwent condensation with thiazolidine-2,4-dione to give the corresponding benzylidenethiazolidinedione derivative, which underwent hydrogenation to give the corresponding benzylthiazolidinedione derivs, which underwent reduction to give rosiglitazone, which was added maleic acid to obtain rosiglitazone maleic acid salt.

IT 1006684-61-2P 1006684-62-3P 1006684-63-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(a process to prepare rosiglitazone maleate)

RN 1006684-61-2 CAPLUS
CN Benzaldehyde, 4-[2-[[(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]- (CA INDEX NAME)



RN 1006684-62-3 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-[[(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]phenyl]methylene]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1006684-63-4 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-[[(4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-2-pyridinylamino]ethoxy]phenyl]methyl]- (CA INDEX NAME)

PAGE 1-A





L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823710 CAPLUS Full-text
DOCUMENT NUMBER: 143:229856
TITLE: Preparation of diaza- or thiazadione derivatives as modulators of 5-HT1A receptor
INVENTOR(S): Lopez Rodriguez, Maria Luz; Benhamu Salama, Bellinda; Del Rio Zambrana, Joaquin; Frechilla Manso, Diana; Marco Martinez, Isabel
PATENT ASSIGNEE(S): Cepa Schwarz Pharma S.L., Spain
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075480	A1	20050818	WO 2005-EP840	20050128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2238015	A1	20050801	ES 2004-205	20040130
ES 2238015	B1	20061101		
AU 2005211486	A1	20050818	AU 2005-211486	20050128
CA 2554217	A1	20050818	CA 2005-2554217	20050128
EP 1711500	A1	20061018	EP 2005-707057	20050128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
BR 2005006495	A	20070213	BR 2005-6495	20050128
CN 1914209	A	20070214	CN 2005-80003594	20050128
JP 2007519679	T	20070719	JP 2006-550114	20050128
MX 2006PA08532	A	20070125	MX 2006-PA8532	20060728
NO 2006003857	A	20061026	NO 2006-3857	20060829
KR 2006134089	A	20061227	KR 2006-717434	20060829

US 20080200470 A1 20080821 US 2007-587792 20070816
PRIORITY APPLN. INFO.: ES 2004-205 A 20040130
WO 2005-EP840 W 20050128
OTHER SOURCE(S): MARPAT 143:229856
GI



I



II

AB Title compds. I [R1 and R2 independently = H or together form 5-6 membered heterocyclic ring, if Y = S then R1 = H and R2 is absent; Y = N or S; W = (CH2)n; n = 0-1; Z = (CH2)m; m = 1-2; X = alkyl, alkenyl or -CH2-phenyl-CH2-; R3 = (un)substituted chroman-2-yl, 2-quinolyl or -O-Ph with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of 5-HT1A receptor. Thus, e.g., II was prepared by substitution of the corresponding alkylamine with the resp. halogenated derivative The activity of I was evaluated in radioligand binding assays towards the 5-HT1A receptor and it was revealed that compds. of the invention displayed Ki values in the range of 0.5 up to 100 nM. I as modulator of 5-HT1A receptor should prove useful as treatment of Parkinson's disease, depression and migraine. Pharmaceutical compns. comprising I are disclosed.

IT 862589-93-3P 862589-94-4P 862589-96-6P
862589-98-8P 862590-00-9P 862590-02-1P
862590-04-3P 862590-06-5P 862590-07-6P
862590-10-1P 862590-11-2P 862590-13-4P
862590-15-6P 862590-17-8P 862590-18-9P
862590-20-3P 862590-21-4P 862590-23-6P
862590-25-8P 862590-28-1P 862590-30-5P
862590-32-7P 862590-33-8P 862590-34-9P
862590-35-0P 862590-37-2P 862590-38-3P
862590-39-4P 862590-40-7P 862590-41-8P
862590-42-9P 862590-43-0P 862590-44-1P
862590-45-2P 862590-46-3P 862590-47-4P
862590-48-5P 862590-49-6P 862590-50-9P
862590-51-0P 862590-52-1P 862590-53-2P
862590-54-3P 862590-57-6P 862590-58-7P
862590-59-8P 862590-60-1P 862590-61-2P
862590-62-3P 862590-63-4P 862590-64-5P
862590-65-6P 862590-66-7P 862590-67-8P

862590-68-9P 862590-69-0P 862590-70-3P
862590-71-4P 862590-72-5P 862590-73-6P
862590-74-7P 862590-75-8P 862590-76-9P
862590-77-0P 862590-78-1P 862591-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaza- or thiazadione derivs. as modulators of 5-HT1A receptor)

RN 862589-93-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 862589-94-4 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-96-6 CAPLUS
CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862589-98-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-00-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-02-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-04-3 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-06-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 862590-07-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]tetrahydro- (CA INDEX NAME)



RN 862590-10-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2E)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-11-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-13-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-15-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-17-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-18-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 862590-20-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 862590-21-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[2-(1-methylethyl)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-23-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)



RN 862590-25-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-28-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



RN 862590-30-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]-,
hydrochloride (1:1) (CA INDEX NAME)



RN 862590-32-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-([1,1'-biphenyl]-2-yloxy)ethyl]amino]butyl]tetrahydro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-33-8 CAPLUS
CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-34-9 CAPLUS
CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-35-0 CAPLUS
CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-37-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-38-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 862590-39-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2Z)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-40-7 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-41-8 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 862590-42-9 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]-,

hydrochloride (1:1) (CA INDEX NAME)



RN 862590-43-0 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-44-1 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro-, hydrochloride
(1:1) (CA INDEX NAME)



RN 862590-45-2 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione,
tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]-, hydrochloride (1:2)
(CA INDEX NAME)



●2 HCl

RN 862590-46-3 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 862590-47-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2R)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 862590-48-5 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-49-6 CAPLUS
CN Pyrrolo[1,2-a]pyrazine-1,4-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]hexahydro- (CA INDEX NAME)



RN 862590-50-9 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]tetrahydro- (CA INDEX NAME)



RN 862590-51-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]tetrahydro- (CA INDEX NAME)



RN 862590-52-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]tetrahydro- (CA INDEX NAME)



RN 862590-53-2 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]octyl]- (CA INDEX NAME)



RN 862590-54-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[[(2S)-3,4-dihydro-2H-1-benzopyran-2-yl]methyl]amino]butyl]tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 862590-57-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2E)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-58-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,

tetrahydro-2-[4-[[2-(2-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-59-8 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
tetrahydro-2-[4-[[2-(3-methoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-60-1 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-61-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(3-bromophenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-62-3 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione,
2-[4-[[2-(2-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-63-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(3-ethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-64-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-[2-(1-methylethoxy)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-65-6 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[[2-[3-(trifluoromethyl)phenoxy]ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-66-7 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-([1,1'-biphenyl]-2-yloxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-67-8 CAPLUS
CN Acetamide, N-[2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



RN 862590-68-9 CAPLUS
CN Acetamide, N-[3-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]phenyl]- (CA INDEX NAME)



RN 862590-69-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[2-(2,3-dimethylphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-70-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-1,4(3H,6H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-71-4 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[(2Z)-4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]-2-buten-1-yl]tetrahydro- (CA INDEX NAME)

Double bond geometry as shown.



RN 862590-72-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]- (CA INDEX NAME)



RN 862590-73-6 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]- (CA INDEX NAME)



RN 862590-74-7 CAPLUS
CN 2,4-Thiazolidinedione, 3-[8-[[2-(2-ethoxyphenoxy)ethyl]amino]octyl]- (CA INDEX NAME)



RN 862590-75-8 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[4-[[2-(2-ethoxyphenoxy)ethyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 862590-76-9 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, 2-[6-[[2-(2-ethoxyphenoxy)ethyl]amino]hexyl]tetrahydro- (CA INDEX NAME)



RN 862590-77-0 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[4-[(2-quinolinylmethyl)amino]butyl]- (CA INDEX NAME)



RN 862590-78-1 CAPLUS
CN Imidazo[1,5-a]pyridine-1,3(2H,5H)-dione, tetrahydro-2-[6-[(2-quinolinylmethyl)amino]hexyl]- (CA INDEX NAME)



RN 862591-00-2 CAPLUS
CN Benzoic acid, 2-[2-[[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]amino]ethoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:143157 CAPLUS Full-text
DOCUMENT NUMBER: 140:181451

TITLE: Preparation of fused heterocycles as 5-HT1A receptor agonists

INVENTOR(S): Del Rio, Zambrana Joaquin; Frechilla Manso, Diana; Lopez Rodriguez, Luz M.; Benhamu Salama, Bellinda; Fuentes Cubero, Jose Angel; Delgado Wallace, Mercedes

PATENT ASSIGNEE(S): Cepa Schwarz Pharma S.L., Spain

SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014915	A1	20040219	WO 2003-ES394	20030729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2199086	A1	20040201	ES 2002-1811	20020731
ES 2199086	B1	20050601		
CA 2492837	A1	20040219	CA 2003-2492837	20030729
AU 2003254512	A1	20040225	AU 2003-254512	20030729
BR 2003013375	A	20050621	BR 2003-13375	20030729
EP 1544201	A1	20050622	EP 2003-784210	20030729
EP 1544201	B1	20060628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671708	A	20050921	CN 2003-818339	20030729
JP 2005539017	T	20051222	JP 2004-526925	20030729
AT 331717	T	20060715	AT 2003-784210	20030729
NZ 538489	A	20060929	NZ 2003-538489	20030729
ES 2271673	T3	20070416	ES 2003-784210	20030729
RU 2322445	C2	20080420	RU 2005-102821	20030729
CN 101172977	A	20080507	CN 2007-10169490	20030729
ZA 2005000784	A	20060830	ZA 2005-784	20050125
US 20050250777	A1	20051110	US 2005-522697	20050127
US 7351732	B2	20080401		
MX 2005PA01245	A	20050912	MX 2005-PA1245	20050131
NO 2005001068	A	20050225	NO 2005-1068	20050225

PRIORITY APPLN. INFO.:

ES 2002-1811	A	20020731
CN 2003-818339	A3	20030729
WO 2003-ES394	W	20030729

OTHER SOURCE(S): MARPAT 140:181451

GI



I



II

AB Title compds. I [wherein R1 = H, (CH2)3, (CH2)4, CH2-S-CH2, S-CH2-CH2; W = N, S; X = (CH2)n; n = 0 or 1; Z = alk(en/yn)yl; R2 = H, aryl, ar/alkyl; Y = (CH2)m; m = 0-2; R = O, CH2; R3 = (un)substituted Ph, naphthyl, tetrahydronaphthyl, furyl, thiophenyl, pyrrolyl, pyridinyl, benzimidazolyl, quinolinyl, isoquinolinyl, chromanyl, etc.] were prepared as agonists of serotonin receptor subtype (5- hydroxytryptamine, 5-HT) 5-HT1A and which are hence useful in the treatment of pathol. states for which an agonist of said receptors is indicated. Twenty-one product characterizations and five biol. examples are given. I were prepared by N-alkylations of amines with organic halides in CH3CN at 60° for 6-24 h (no specific examples are given). In an in vitro test, II inhibited the forskolin-stimulated adenylate cyclase activity of He-La cells transfected with the human 5HT1A receptor with CE50 = 16.3 nM. In a rat permanent focal ischemic model for middle cerebral artery occlusion, II exhibited a 25% reduction in the infarct volume when administered i.v.. Thus, I are neuroprotective agents used for treatment and prophylaxis of cerebral damage caused by ischemic or traumatic stroke.

IT 658714-55-7P, (±)-2-[4-[(Chroman-2-yl)methylamino]butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazole 658714-56-8P, (.-+.)-2-[4-[[(Chroman-2-yl)methyl]amino]butyl]-1,3-dioxoperhydroimidazo[1,5-b]thiazole 658714-57-9P, (.-+.)-2-[4-[[(Chroman-2-yl)methyl]amino]butyl]-1,3-dioxoperhydroimidazo[1,5-c]thiazole 658714-58-0P, (±)-3-[4-[[(Chroman-2-yl)methyl]amino]butyl]-2,4-dioxothiazolidine 658714-60-4P, (±)-3-[6-[[(Chroman-2-yl)methyl]amino]hexyl]-2,4-dioxothiazolidine 658714-66-0P 658714-67-1P, 3-[4-[2-(Phenoxy)ethylamino]butyl]-2,4-dioxothiazolidine 658714-76-2P 658714-77-3P 658714-78-4P 658714-79-5P 658714-80-8P 658714-81-9P 658714-87-5P 658714-88-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT1A receptor agonist; preparation of fused heterocycles as 5-HT1A receptor agonists)

RN 658714-55-7 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro- (CA INDEX NAME)



RN 658714-56-8 CAPLUS
CN Imidazo[1,5-b]isothiazole-4,6(2H,5H)-dione, 5-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro- (CA INDEX NAME)



RN 658714-57-9 CAPLUS
CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)



RN 658714-58-0 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]- (CA INDEX NAME)



RN 658714-60-4 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]- (CA INDEX NAME)



RN 658714-66-0 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-67-1 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]- (CA INDEX NAME)



RN 658714-76-2 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



RN 658714-77-3 CAPLUS
CN Imidazo[1,5-b]isothiazole-4,6(2H,3aH)-dione, 5-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-78-4 CAPLUS
CN 1H,3H-Imidazo[1,5-c]thiazole-5,7(6H,7aH)-dione, 6-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-79-5 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-80-8 CAPLUS
CN 2,4-Thiazolidinedione, 3-[5-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]pentyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-81-9 CAPLUS
CN 2,4-Thiazolidinedione, 3-[6-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]hexyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 658714-87-5 CAPLUS
CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, tetrahydro-2-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1), (7aS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 658714-88-6 CAPLUS
CN 2,4-Thiazolidinedione, 3-[4-[(2-phenoxyethyl)amino]butyl]-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:388180 CAPLUS Full-text
DOCUMENT NUMBER: 131:44735
TITLE: Preparation of aminoalkylbenzopyrans and analogs as gastric fundus relaxants
INVENTOR(S): Wigerinck, Piet Tom Bert Paul; Verschueren, Wim Gaston; Schroven, Marc Francis Josephine; De Bruyn, Marc Frans Leopold
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929687	A1	19990617	WO 1998-EP7771	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6133277	A	20001017	US 1998-192686	19981116
TW 577886	B	20040301	TW 1998-87119526	19981125
CA 2311669	A1	19990617	CA 1998-2311669	19981127
AU 9924127	A	19990628	AU 1999-24127	19981127
AU 748669	B2	20020606		
EP 1036073	A1	20000920	EP 1998-966603	19981127
EP 1036073	B1	20060726		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
BR 9814256	A	20001003	BR 1998-14256	19981127
TR 200001542	T2	20010122	TR 2000-1542	19981127
EE 200000328	A	20010815	EE 2000-328	19981127
EE 4438	B1	20050215		
JP 2001525407	T	20011211	JP 2000-524281	19981127
HU 2000004492	A2	20020328	HU 2000-4492	19981127
HU 224813	B1	20060228		
IL 136529	A	20030312	IL 1998-136529	19981127
CN 1155597	C	20040630	CN 1998-811831	19981127

PL 191144	B1	20060331	PL 1998-341007		19981127
AT 334125	T	20060815	AT 1998-966603		19981127
ES 2270541	T3	20070401	ES 1998-966603		19981127
CZ 297895	B6	20070425	CZ 2000-2018		19981127
SK 286268	B6	20080606	SK 2000-803		19981127
ZA 9811081	A	20000622	ZA 1998-11081		19981203
IN 1998DE03657	A	20070302	IN 1998-DE3657		19981203
NO 2000002074	A	20000602	NO 2000-2074		20000419
NO 320727	B1	20060123			
BG 104372	A	20001229	BG 2000-104372		20000424
BG 64624	B1	20050930			
HR 2000000340	A1	20010430	HR 2000-340		20000525
MX 2000PA05524	A	20020225	MX 2000-PA5524		20000605
US 6495547	B1	20021217	US 2000-641485		20000818
HK 1028400	A1	20061110	HK 2000-107845		20001207
US 20030083365	A1	20030501	US 2002-116590		20020403
US 6747045	B2	20040608			
US 20030149093	A1	20030807	US 2002-235623		20020905
US 6852714	B2	20050208			
PRIORITY APPLN. INFO.:			EP 1997-203808	A	19971205
			US 1998-192686	A3	19981116
			WO 1998-EP7771	W	19981127
			US 2000-641485	A3	20000818

OTHER SOURCE(S): MARPAT 131:44735

GI



I

AB Title compds. [I; R = Z1AR5; R1 = H or 1-3 of halo, alkyl, alkoxy, etc.; R4 = H or alkyl; R5 = N-attached oxodiazacycloalkyl, etc.; R6 = H, alkyl, CH2Ph, alkoxycarbonyl, etc.; Z = (CH2)1-3, OCH2, CH:CH, CHR3, etc.; R3R4 = bond; Z1 = CO, alkylene, etc.; Z2 = alkylene; Z3 = piperidine-1,n-diyl] were prepared Thus, (R)-3,4-dihydro-2H-1-benzopyran-2-ylmethyl methanesulfonate (preparation given) was aminated by 1-(3-aminopropyl)tetrahydro-2(1H)-pyrimidinone to give I [R = R1 = H, R4 = CH2NH(CH2)3R5, R5 = 2-oxotetrahydro-1-pyrimidinyl]. Data for biol. activity of I were given.

IT 227298-10-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoalkylbenzopyrans and analogs as gastric fundus relaxants)

RN 227298-10-4 CAPLUS

CN 2,4-Imidazolidinedione, 3-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]propyl]-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:716906 CAPLUS Full-text
DOCUMENT NUMBER: 123:97798
ORIGINAL REFERENCE NO.: 123:17191a,17194a
TITLE: Color photographic material
INVENTOR(S): Kaneko, Yutaka; Asatake, Atsushi; Sugino, Motoaki
PATENT ASSIGNEE(S): Konishiroku Photo Ind, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 56 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07128820	A	19950519	JP 1993-270871	19931028

PRIORITY APPLN. INFO.: JP 1993-270871 19931028
GI



AB In the title color photog. material comprising ≥1 Ag halide emulsion layers on its support, ≥1 of the emulsion layers contains an acylacetoamide yellow coupler such as I (R = H, aliphatic, aromatic, heterocyclic group; R1 = aliphatic, aromatic, heterocyclic group; j = 0-8; R2, X = benzene ring substituent group; k = 0-4; Y = O, NR3, S(O)l; R3 = H, aliphatic, aromatic, or heterocyclic group, sulfonyl, sulfinyl, phosphonyl, acyl, oxycarbonyl, carbamoyl, sulfamoyl; l = 0-2; W = H, group releasable on coupling reaction with oxidized developing agent). This photog. material shows high color d. and low fog level.
IT 165741-47-9 165741-52-6
RL: DEV (Device component use); USES (Uses)
(yellow photog. coupler)
RN 165741-47-9 CAPLUS
CN Carbamic acid, [2-[3-[[2-chloro-5-[(1-oxotetradecyl)amino]phenyl]amino]-2-

[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-1,3-dioxopropyl]-2-methyl-1,3-propanediyl]bis-, diphenyl ester (9CI) (CA INDEX NAME)



RN 165741-52-6 CAPLUS
CN Carbamic acid, [2-[2-[2,5-dioxo-3-(phenylmethyl)-1-imidazolidinyl]-1,3-dioxo-3-[[5-[(1-oxotetradecyl)amino]-2-propoxyphenyl]amino]propyl]-1,1,2,3,3-pentamethyl-1,3-propanediyl]bis-, diphenyl ester (9CI) (CA INDEX NAME)



=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 11:53:59 ON 13 JAN 2009